Who is affected by this change?

This affects Independence Blue Cross Neurology, Oncology providers on Medicare Advantage plans.

When does this change take effect?

This change is effective Oct 1, 2025.

Back to dashboard

Medicare AdvantageCoverageMedium impact

MA08.160b, Ublituximab-xiiy (Briumvi ®) for intravenous use

Independence Blue Cross·Neurology, Oncology·Pharmacy

Effective date

Oct 1, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

Medicare Advantage policy MA08.160b for Ublituximab-xiiy (Briumvi) for intravenous use has been updated. This affects coverage and billing for this specialty medication used for multiple sclerosis treatment.

Action Required

Action needed

By October 1, 2025: Billing team must review updated Medicare Advantage coverage criteria for Ublituximab-xiiy (Briumvi) infusions. Contact insurance to verify prior authorization requirements and coverage guidelines. Update billing procedures for this specialty drug administration.

Related policy hubs

Independence Blue Cross policies Neurology Oncology